Aurélia Bidant

Aurélia Bidant

Director Pharmacovigilance

Key Knowledge Areas:

- Pharmacovigilance
- Early access programme /ATU
- Medical Information

Aurélia is a pharmacist and completed her Pharmaceutical education at the Châtenay-Malabry Faculty, France (Thesis on “Audit et Inspection en pharmacovigilance”). She also holds a DU in “Pharmacovigilance, interactions et contre-indications des médicaments” from Limoges (2004) as well as a Master Degree in Regulatory Affairs Health Industry at the University of Sceaux, France (2000).

 

Aurélia has more than 12 years of experience in Pharmacovigilance and Medical Information, especially in the field of Pharmacovigilance in France and in Europe and management of Medical Information activities for pharmaceutical products.

 

Aurélia started her professional career in 2000 where she worked in Regulatory Affairs at Abbott France. Then she joined the Pharmacovigilance and Medical Information department in 2001 and took over its leadership in 2004.

Her expertise covered submission of individual case safety reports and PV reports as well as the activity improvement within a Pharmacovigilance and Medical Information department.

 

Aurélia has therefore been able to set up tools such as local database, quality and performance indicators to better meet the regulatory pharmacovigilance systems requirements as well as adverse events declaration obligations.

 

In 2007, she joined Allergan as responsible of the company Pharmacovigilance and Medical Information. Aurélia was also in charge of the control of the advertising and of the sales representatives training documentation. Within the Specific Code of Practice context (Charte de la Visite Médicale), she was also been appointed Medical and Scientific Responsible of the company by the Qualified Pharmacist. In this role, Aurélia was in charge of the evaluation of the quality information delivered by the sales representatives.

 

In 2010, Aurélia moved to consultancy and joined BLUE-REG PHARMA CONSULT in 2012.

Discover our last white Paper

Learn more